The Rituximab and chronic fatigue syndrome (ME/CFS) story began when two Norwegian oncologists, Drs. Fluge and Mella, found that Rituximab cured cancer AND ME/CFS in some of their patients. Two small and very successful trials later they embarked on a large placebo-controlled, Phase III clinical...
For a few years some of us were excited about what was coming out about Rituximab. I know the Phase 3 trial failed, but did anything come out about any subgroups having a positive outcome? I also saw some stories about it harming some subgroups. I am getting close to having the opportunity to...
Boy is this interesting
Gradisnuk-Staines group in Australia is reporting the Rituximab is whacking the already whacked out NK cells in ME/CFS patients. It appears that the group tracked NK cell functioning in patients given the drug and found that it significantly worsened.
At one time it was...
Sad news...
No magic bullet yet for ME/CFS
The outcome of a positive Rituximab trial for ME/CFS - possibly, finally, an FDA approved drug, relief for many, acceptance for this disease, increased research fund - would have been spectacular but Dr. Mella reported this week in Norway that the...
hello everyone
I've been reading this site for many years and want to introduce my story and ask for help with ideas for treatment, research relevant to my case, medication that may help me, and anything else people would like to comment on. the more info the better, especially around...
U.K. Rituximab ME/CFS Trial Hits Roadblocks
Considerable funding has been gathered for studying B-cells in ME/CFS patients and hopefully for creating a Rituximab trial in the U.K. Late late year the ME Association called for a UK Rituximab trial to begin soon.
Dr. Cambridge, a UK...
Update from Haukeland University regarding the Rituximab and other studies
The Rituximab Study
For those who don't remember (such as myself - another blog I wrote that I promptly forgot) here's the study:
The first two infusions (500 mg/m2, max 1000 mg, or placebo) are given two weeks...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.